Olema Oncology Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
112
- Stock Symbol
-
OLMA
- Share Price
-
$4.42
- (As of Thursday Closing)
Olema Oncology General Information
Description
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Contact Information
Website
www.olema.comCorporate Office
- 780 Brannan Street
- San Francisco, CA 94103
- United States
Corporate Office
- 780 Brannan Street
- San Francisco, CA 94103
- United States
Olema Oncology Timeline
Olema Oncology Stock Performance
As of 17-Apr-2025, Olema Oncology’s stock price is $4.42. Its current market cap is $302M with 68.3M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.42 | $4.26 | $2.86 - $16.62 | $302M | 68.3M | 1.02M | -$2.20 |
Olema Oncology Financials Summary
As of 31-Dec-2024, Olema Oncology has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 217,229 | 217,229 | 494,142 | (120,654) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (141,763) | (141,763) | (104,603) | (106,658) |
| Net Income | (129,474) | (129,474) | (96,655) | (104,787) |
| Total Assets | 450,979 | 450,979 | 276,945 | 215,645 |
| Total Debt | 1,429 | 1,429 | 2,417 | 2,565 |
Olema Oncology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Olema Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Olema Oncology Comparisons
Industry
Financing
Details
Olema Oncology Competitors (71)
One of Olema Oncology’s 71 competitors is Black Diamond Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Black Diamond Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| JW Therapeutics | Formerly VC-backed | Shanghai, China | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX | ||||
| BriaCell Therapeutics | Corporation | West Vancouver, Canada | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom |
Olema Oncology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Olema Oncology Patents
Olema Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023356291-A1 | Methods of treating estrogen receptor-mediated disorders | Pending | 05-Oct-2022 | ||
| AU-2023324857-A1 | 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer | Pending | 19-Aug-2022 | ||
| AU-2023324856-A1 | 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer | Pending | 19-Aug-2022 | ||
| AU-2023324854-A1 | Estrogen receptor modulators and uses thereof | Pending | 19-Aug-2022 | ||
| AU-2023271967-A1 | Salts and solid forms of an estrogen receptor antagonist | Pending | 20-May-2022 | C07D471/04 |
Olema Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Olema Oncology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Olema Oncology ESG
Risk Overview
Risk Rating
Updated October, 15, 2024
38.54 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Pharmaceuticals
Subindustry
of 430
Rank
Percentile
Olema Oncology FAQs
-
When was Olema Oncology founded?
Olema Oncology was founded in 2006.
-
Where is Olema Oncology headquartered?
Olema Oncology is headquartered in San Francisco, CA.
-
What is the size of Olema Oncology?
Olema Oncology has 112 total employees.
-
What industry is Olema Oncology in?
Olema Oncology’s primary industry is Biotechnology.
-
Is Olema Oncology a private or public company?
Olema Oncology is a Public company.
-
What is Olema Oncology’s stock symbol?
The ticker symbol for Olema Oncology is OLMA.
-
What is the current stock price of Olema Oncology?
As of 17-Apr-2025 the stock price of Olema Oncology is $4.42.
-
What is the current market cap of Olema Oncology?
The current market capitalization of Olema Oncology is $302M.
-
Who are Olema Oncology’s competitors?
Black Diamond Therapeutics, JW Therapeutics, Rein Therapeutics, BriaCell Therapeutics, and Immunocore Holdings are some of the 71 competitors of Olema Oncology.
-
What is Olema Oncology’s annual earnings per share (EPS)?
Olema Oncology’s EPS for 12 months was -$2.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
